Balrampur Chini 2026: PLA capex ₹3,080cr, ₹650cr plan

What the company announced

Balrampur Chini Mills Limited (BCML) has increased the estimated cost of its Polylactic Acid (PLA) project by ₹230 crore, taking total project cost to ₹3,080 crore from ₹2,850 crore. The update was discussed in a management conference call held on April 28, 2026, focused on project progress and capital-raising plans. Alongside the capex revision, the board approved multiple funding and expansion decisions linked to the PLA project ecosystem. These include a ₹450 crore preferential allotment of equity shares at ₹483 per share and an enabling resolution to raise up to ₹200 crore through debentures. The company also approved a new lactogypsum processing plant at Kumbhi, Uttar Pradesh, with an investment outlay of up to ₹160 crore. Management said PLA plant commissioning remains on track for quarter three. The combination of revised capex, new byproduct utilisation plans, and financing approvals signals a wider diversification push beyond the company’s existing sugar-linked operations.

PLA project cost revised after ₹230 crore escalation

BCML revised the PLA project cost to ₹3,080 crore, reflecting a cost escalation of about ₹230 crore over the earlier estimate. The company attributed the escalation to higher prices of key construction materials, global supply chain disruptions, and changes in engineering and designing incorporated during a modelling review. Management indicated machinery is expected to arrive soon, and that the revision should represent the final revision in project cost. The PLA facility is being developed at Kumbhi in Uttar Pradesh. The plant is designed for a capacity of 80,000 tonnes per annum. The company also stated that the revised costs remain eligible for a 50% capital subsidy under the Uttar Pradesh bioplastic policy. While the cost increase raises funding requirements, the company positioned it as an adjustment driven by execution realities rather than a change in project scope.

Commissioning timeline: quarter three remains the target

On the April 28, 2026 call, management said commissioning for the PLA plant remains on track for quarter three. It also noted that machinery is expected to arrive soon, suggesting the project is moving into the final equipment installation phase. The company did not provide a revised commissioning quarter, but reiterated the earlier timeline. Separately, the lactogypsum processing plant linked to PLA byproduct utilisation is expected to begin commercial production in 18 months. In other disclosures, BCML has also indicated a target of December 2027 for the lactogypsum plant’s commercial production. Together, these timelines imply that the PLA plant is expected to come online earlier, with downstream byproduct conversion scaling up after stabilisation of PLA operations.

Preferential equity issue: ₹450 crore at ₹483 per share

To support the PLA project and new initiatives, BCML’s board approved a preferential allotment of equity shares worth approximately ₹450 crore. The issue price is ₹483 per share, described as the SEBI price. The company also disclosed the proposed issuance of up to 93,16,771 equity shares under the plan, subject to shareholder approval. The board meeting that cleared the fundraise was held on April 23, 2026. BCML has scheduled an Extra-Ordinary General Meeting (EGM) for May 20, 2026, to seek shareholder approval, along with required regulatory clearances. The company stated that the proceeds are intended to support expansion initiatives, including funding needs arising from the PLA project cost revision and the new lactogypsum facility.

Promoter participation to maintain 43% stake

BCML said promoters will participate in the fundraise and maintain their stake at 43%. Based on the disclosed structure, promoter participation is expected to be about ₹193 crore out of the ₹450 crore equity raise. The company has indicated that the preferential issue will be allocated to a mix of promoters, promoter group entities, and institutional investors. Named institutional participants disclosed in the information shared include Tata Small Cap Fund, ICICI Prudential funds, Ikigai Emerging Equity Fund, and Alchemy and 360 One investment funds. The company presented the promoter participation as a key element supporting capital raising execution, while keeping the post-issue ownership structure stable.

Debenture enabling resolution: up to ₹200 crore

In addition to the equity raise, the board approved an enabling resolution to raise up to ₹200 crore through non-convertible debentures (NCDs). The plan is to issue NCDs on a private placement basis, in one or more tranches. The company described the proposed NCDs as secured and listed, adding a debt option alongside the preferential issue. With this approval, BCML has board-level authorisation to mobilise debt when required, providing timing flexibility relative to project cash flow needs. The company has also said that revised PLA capex, including escalations, will be funded through a combination of preferential equity, debt, and internal accruals.

Lactogypsum plant at Kumbhi: ₹160 crore for gypsum boards

BCML’s board approved setting up a lactogypsum processing plant at Kumbhi, Uttar Pradesh, with an estimated investment outlay of up to ₹160 crore. The facility will convert lactogypsum into gypsum boards. Lactogypsum is described by the company as a synthetic and eco-friendly byproduct generated during the PLA manufacturing process, positioning the new facility as a downstream, byproduct-utilisation unit. The plant is expected to have a production capacity of approximately 76 lakh gypsum boards per annum. In the investor discussion, the company also referenced a gypsum board capacity of 63 lakh pieces per annum, linked to an input-output explanation around lactogypsum volumes. The company has indicated that up to ₹160 crore of the preferential issue proceeds may be used to fund the lactogypsum plant.

Output, revenue potential, and payback disclosed by management

BCML disclosed operating-linked projections for the byproduct stream expected from the PLA plant. Lactogypsum output is estimated at around 1.16 to 1.2 lakh tonnes. Management indicated a gypsum board revenue potential of around ₹150 crore per annum for the downstream product line. The company also referred to a payback period of five years for the lactogypsum initiative. These metrics were shared as part of the rationale for adding a value chain around the PLA byproduct rather than treating it as waste. The company linked the initiative to operational integration at the Kumbhi site, where both PLA production and byproduct processing are planned.

Key facts table

Timeline and upcoming milestones

Market impact: funding mix and capex discipline

The immediate market-relevant takeaway is the increased funding requirement after the PLA capex moved to ₹3,080 crore. BCML has responded by aligning a multi-source financing plan: ₹450 crore in equity via preferential allotment, up to ₹200 crore via NCDs, and the balance through debt and internal accruals as stated by the company. The preferential issue price of ₹483 per share and the disclosed share count cap provide clarity on dilution mechanics for investors assessing capital structure changes. Promoter participation at about ₹193 crore, while maintaining a 43% stake, indicates the company’s intention to keep control levels unchanged post-fundraise. The lactogypsum plant adds another capex commitment of up to ₹160 crore, with BCML indicating that up to the same amount of preferential issue proceeds may be allocated to this facility. On the operational side, management reaffirmed quarter three commissioning for the PLA plant and noted machinery is expected to arrive soon, which matters for capex-to-revenue transition timelines.

Analysis: why the lactogypsum decision matters for the PLA ecosystem

BCML’s lactogypsum investment connects directly to how the company plans to manage and monetise PLA byproducts at scale. By outlining lactogypsum output of 1.16 to 1.2 lakh tonnes and pairing it with gypsum board capacities (76 lakh boards per annum, with an additional reference to 63 lakh pieces per annum), the company is framing the byproduct stream as a predictable feedstock for a second revenue line. Management’s disclosed revenue potential of around ₹150 crore per annum and a five-year payback period provide a benchmark for evaluating whether the downstream unit improves overall return metrics on the Kumbhi complex. The strategy also reduces the risk of byproduct handling becoming a cost centre, although the company has not disclosed operating margins for the gypsum product line. Separately, the statement that revised PLA costs remain eligible for a 50% capital subsidy under the UP bioplastic policy is relevant because it suggests the cost escalation does not automatically weaken the project’s policy-linked economics, based on the company’s eligibility assessment.

Conclusion

Balrampur Chini’s April 2026 disclosures outline three linked moves: a ₹230 crore PLA capex escalation to ₹3,080 crore, a ₹650 crore total funding headroom through ₹450 crore preferential equity and ₹200 crore debentures, and a ₹160 crore lactogypsum processing plant at Kumbhi. Management has reiterated that PLA commissioning is on track for quarter three, while the lactogypsum unit is expected to start commercial production in about 18 months, with a stated timeline of December 2027 in company updates. The next formal milestone is the May 20, 2026 EGM for shareholder approval of the preferential allotment, after which the company can proceed with equity issuance and further funding steps as needed.